Probucol

Generic Name: Probucol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₄₈O_₂S_₂

CAS Number: 23288-49-5

Unique Ingredient Identifier: P3CTH044XJ

Background: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Indication: Used to lower LDL and HDL cholesterol.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke

Not yet recruiting

Conditions: Ischemic Stroke
Lipid Disorder
Atherosclerosis of Artery
Statin

Interventions: Drug: Statin
Drug: Probucol

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Xuanwu Hospital, Beijing

Target Recruit Count: 200

Registration Number: NCT06604117

Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis

Phase 3

Recruiting

Conditions: Ischemic Stroke
TIA

Interventions: Drug: Placebo probucol
Drug: Probucol

First Posted Date: 2024-01-26

Last Posted Date: 2024-07-15

Lead Sponsor: First Affiliated Hospital of Wannan Medical College

Target Recruit Count: 5452

Registration Number: NCT06225752

Locations: 🇨🇳
The First Affliated Hospital of Wannan Medical College, Wuhu, China

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

Phase 4

Recruiting

Conditions: Stroke, Ischemic
Atherosclerosis, Cerebral

Interventions: Drug: Atorvastatin Calcium
Drug: Probucol
Drug: PCSK9 inhibitor

First Posted Date: 2018-11-27

Last Posted Date: 2024-02-23

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 100

Registration Number: NCT03753555

Locations: 🇨🇳
General Hospital of ShenYang Military Region, ShenYang, China

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1

Completed

Conditions: Dementia of the Alzheimer Type
Age-related Cognitive Decline
Mild Cognitive Impairment Due to Alzheimer Disease

Interventions: Drug: Probucol

First Posted Date: 2016-03-14

Last Posted Date: 2018-01-31

Lead Sponsor: Douglas Mental Health University Institute

Target Recruit Count: 23

Registration Number: NCT02707458

Locations: 🇨🇦
Douglas Hospital Research Centre, Montreal, Quebec, Canada

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Phase 4

Conditions: Brain Ischemia
Intracranial Hemorrhages

Interventions: Drug: cilostazol
Drug: Probucol
Drug: Aspirin
Drug: Placebo of aspirin
Drug: placebo of cilostazol
Device: Intima-medial thickness

First Posted Date: 2015-06-26

Last Posted Date: 2015-12-24

Lead Sponsor: Asan Medical Center

Target Recruit Count: 800

Registration Number: NCT02483169

Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probucol

First Posted Date: 2012-05-03

Last Posted Date: 2013-06-05

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 12

Registration Number: NCT01590901

Locations: 🇨🇳
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing, China

Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Placebo
Drug: Probucol

First Posted Date: 2011-05-06

Last Posted Date: 2013-06-05

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 264

Registration Number: NCT01349010

Locations: 🇨🇳
The Sencond Xiangya Hospital of Central South University, Changsha, Hunan, China

Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

Phase 4

Completed

Conditions: Hyperlipidemias

Interventions: Drug: HMG-CoA Reductase Inhibitor
Drug: Probucol
Drug: Cilostazol

First Posted Date: 2011-02-08

Last Posted Date: 2019-09-20

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 342

Registration Number: NCT01291641

Locations: 🇰🇷
Dong-A Medical Center, Seogu, Busan, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Boramae Medical Center, Seoul, Korea, Republic of

and more 2 locations

A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Probucol
Drug: Probucol and Cilostazol

First Posted Date: 2010-12-02

Last Posted Date: 2013-05-08

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 353

Registration Number: NCT01252056

Locations: 🇨🇳
Beijing Universuty First Hospital, Beijng, Beijing, China

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

Phase 4

Conditions: Brain Ischemia
Intracranial Hemorrhages

Interventions: Drug: Cilostazol
Drug: Probucol
Drug: Aspirin
Drug: placebo of aspirin
Drug: placebo of cilostazol
Device: ankle-brachial index (ABI)
Device: intima-medial thickness (IMT)
Device: new asymptomatic brain hemorrhage
Device: new ischemic lesions on follow-up FLAIR images

First Posted Date: 2009-11-13

Last Posted Date: 2015-12-24

Lead Sponsor: Asan Medical Center

Target Recruit Count: 1600

Registration Number: NCT01013532

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of
🇰🇷
Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of

and more 68 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy